Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
SH3BGRL3
Introduction
SH3 domain-binding glutamic acid-rich-like protein 3 is a protein that in humans is encoded by the SH3BGRL3 gene.[1]
The 10.5kDa protein SH3 binding glutamic acid-rich protein-like 3 has an isoelectric point of 5.0. SH3 binding glutamic acid-rich (SH3BGR) gene is located to human chromosome 21. Two homologous genes, SH3BGRL and SH3BGRL3 are located to chromosome Xq13.3 and 1p34.3-35, respectively and code for small proteins similar to the N-terminal region of the SH3BGR protein.[2] SH3BGRL3 protein shows a significant similarity to glutaredoxin 1 of E. coli, and all the three proteins are predicted to belong to thioredoxin-like protein family. Glutaredoxins (GRXs) are ubiquitous oxidoreductases, which catalyze the reduction of many intra-cellular protein disulfides and play an important role in many redox pathways. However, the SH3BGRL3 protein lacks the enzymatic function of glutaredoxins and may have a role as a regulator of redox activity.[3]
Role in cancer
Role in cancer
Proteins such as glutaredoxin and thioredoxin are reported as up-regulated in many cancers such as lung and pancreatic; they have been implicated in increased resistance of cancer cells to free-radicals. There is little current evidence which directly links SH3GRPL3 with survival in cancer cells, however the protein has recently been identified as up-regulated in glioblastoma multiforme compared to normal cerebral tissue on proteomic analysis.[4] Studies of acute promyelocytic leukemia cell line NB4 have also reported up-regulation of the protein. Conversely, the related protein SH3BGRL is reported to be downregulated in fibroblasts, lymphoid cells, and splenic tumor cells transformed by the viral oncogene v-Rel.[5] Co-expression of SH3BGRL with v-Rel in primary splenic lymphocytes reduced the number of colonies formed by 76%. Xu et al. reported SH3BGRPL3 protein as a post-translational modification of the 27kDa tumor necrosis factor alpha (TNF-α) inhibitory protein, TIP-B1. This protein is potentially involved in resistance of cells to the apoptosis-inducing affect of TNF-α.[6]
References
References
- ↑ “Entrez Gene: SH3BGRL3 SH3 domain binding glutamic acid-rich protein like 3”.
- ↑ Egeo A, Mazzocco M, Arrigo P, Vidal-Taboada JM, Oliva R, Pirola B, Giglio S, Rasore-Quartino A, Scartezzini P (June 1998). “Identification and characterization of a new human gene encoding a small protein with high homology to the proline-rich region of the SH3BGR gene”. Biochem. Biophys. Res. Commun. 247 (2): 302–6. doi:10.1006/bbrc.1998.8763. PMID 9642120.
- ↑ Mazzocco M, Maffei M, Egeo A, Vergano A, Arrigo P, Di Lisi R, Ghiotto F, Scartezzini P (May 2002). “The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to Thioredoxin Superfamily”. Gene. 291 (1–2): 233–9. doi:10.1016/S0378-1119(02)00602-9. PMID 12095696.
- ↑ Khalil AA, James P (February 2007). “Biomarker discovery: a proteomic approach for brain cancer profiling”. Cancer Sci. 98 (2): 201–13. doi:10.1111/j.1349-7006.2007.00374.x. PMID 17233837.
- ↑ Majid SM, Liss AS, You M, Bose HR (February 2006). “The suppression of SH3BGRL is important for v-Rel-mediated transformation”. Oncogene. 25 (5): 756–68. doi:10.1038/sj.onc.1209107. PMID 16186799.
- ↑ Xu C, Zheng P, Shen S, Xu Y, Wei L, Gao H, Wang S, Zhu C, Tang Y, Wu J, Zhang Q, Shi Y (May 2005). “NMR structure and regulated expression in APL cell of human SH3BGRL3”. FEBS Lett. 579 (13): 2788–94. doi:10.1016/j.febslet.2005.04.011. PMID 15907482.
Further reading
Further reading
- Xu C, Zheng P, Shen S, et al. (2005). “NMR structure and regulated expression in APL cell of human SH3BGRL3”. FEBS Lett. 579 (13): 2788–94. doi:10.1016/j.febslet.2005.04.011. PMID 15907482.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”. Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Mazzocco M, Arrigo P, Egeo A, et al. (2001). “A novel human homologue of the SH3BGR gene encodes a small protein similar to Glutaredoxin 1 of Escherichia coli”. Biochem. Biophys. Res. Commun. 285 (2): 540–5. doi:10.1006/bbrc.2001.5169. PMID 11444877.
- Henn AD, Berleth ES, Mihich E, Ehrke MJ (2001). “Changes in cytosolic and membrane TNF inhibitory protein-B1 (TIP-B1) levels associated with protection from TNF-induced cytotoxicity”. FASEB J. 15 (7): 1315–7. doi:10.1096/fj.00-0543fje. PMID 11344125.
- Seo J, Kim M, Kim J (2001). “Identification of novel genes differentially expressed in PMA-induced HL-60 cells using cDNA microarrays”. Mol. Cells. 10 (6): 733–9. doi:10.1007/s10059-000-0733-x. PMID 11211881.
- Berleth ES, Henn AD, Gurtoo HL, et al. (2001). “A novel tumor necrosis factor-alpha inhibitory protein, TIP-B1”. Int. J. Immunopharmacol. 22 (12): 1137–42. doi:10.1016/S0192-0561(00)00071-0. PMID 11137621.
- Berleth ES, Nadadur S, Henn AD, et al. (1999). “Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis”. Cancer Res. 59 (21): 5497–506. PMID 10554026.